Previous 10 | Next 10 |
AMC Entertainment Holdings (AMC) +240%.Koss Corporation (KOSS) +117%.Express (EXPR) +91%.GameStop (GME) +55%.Vislink Technologies (VISL) +22% as shipping of Satellite communications equipment begins.Revlon (REV) +16%.J.Jill (JILL) +17%.Accelerate Diagnostics (AXDX) +17%.Pitney ...
Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID study Up to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic Sydney...
Gainers: [[BBBY]] +17.7%. [[IMMP]] +15.8%. [[FHTX]] +7.6%. [[TLSA]] +6.8%. [[ADMS]] +6.8%.Losers: [[TTOO]] -20.3%. [[VIR]] -17.0%. [[GRTX]] -16.6%. [[AGIO]] -8.4%. [[WMG]] -7.7%. For further details see: BBBY, IMMP, TTOO and VIR among after-hours movers
Immutep (IMMP) drops 6% in premarket after its licensing partners, GSK, has decided to discontinue its Phase 2 trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, derived from Immutep’s IMP731 antibody, in patients with active ulcerative colitis. The...
Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trials TACTI-002 study expanded in lung cancer New phase II trial in head and neck cancer announced EOC Pharma starts new phase II study in metastatic breast cancer Rob...
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing par...
Today, we take an in depth look at a small oncology concern named Immutep Limited. The company has shown some recent progress in advancing its pipeline and also recently disclosed some positive late stage trial results. A full investment analysis on this "off the radar" small-cap ...
Immutep ([[IMMP]]) completes recruitment for stage 2 of Part C of its TACTI-002 mid-stage study of its lead product candidate, eftilagimod alpha ((“efti” or “IMP321”)) in combination with Merck & Co's (MRK) KEYTRUDA ((pembrolizumab)).The portion of th...
Completes recruitment of patients with 2nd line head and neck squamous cell carcinoma (HNSCC) Recruitment of additional 1 st line non small cell lung cancer (NSCLC) patients started Further interim data from TACTI-002 expected in H1 2021 Sydney, AUSTRALIA, Jan. 07, 202...
Are These The Best Biotech Penny Stocks To Buy Right Now? As we turn the page on 2020, there are quite a lot of penny stocks in focus. One of the interesting things for investors to consider is that there are several industries that have seen bullish sentiment in the past few months...
News, Short Squeeze, Breakout and More Instantly...
Media Release Study expected to enrol first participants during Q3 CY2024 SYDNEY, AUSTRALIA, July 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing no...
2024-07-12 10:45:04 ET QuantumScape Corp (QS) QS is trading UP for the last 5 days, and it at trading at $7.84 with volume of 22,322,158 and a one day change of $0.78 (10.98%). QuantumScape Corp has a 52-week low of 4.67 and a 52-week high of $13.86. The business's 50-day moving ave...
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response...